Published Analysis Of Sotagliflozin Clinical Data Demonstrates Significant Reductions In The Risk Of Hospital Readmissions For Heart Failure
Portfolio Pulse from Benzinga Newsdesk
A post-hoc analysis of SOLOIST-WHF clinical data published in the Journal of the American College of Cardiology shows that Sotagliflozin significantly reduces the risk of hospital readmissions for heart failure. The risk reductions are approximately 50% for heart failure readmissions and for the composite of CV death and heart failure readmissions at 30- and 90-days following hospital discharge.
August 08, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive clinical data on Sotagliflozin, a product of Lexicon Pharmaceuticals, could potentially boost the company's stock in the short term.
The positive clinical data on Sotagliflozin, a product of Lexicon Pharmaceuticals, indicates the drug's effectiveness in reducing hospital readmissions for heart failure. This could potentially increase the demand for the drug, leading to increased revenues for the company and a potential boost in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100